RxDoctor Payments Data

Morad Askari, MD

Surgery of the Hand · Coral Gables, FLNPI 1174715551

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (43.7%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 39 manufacturers reported payments, led by Kerecis Limited at 25.0% of the total. Reporting peaked in 2019 at $11,292 and has fallen 76.7% since, to $2,629 in 2025.

$36,249in general payments, 2019–2025

Across 249 payments — averaging $145.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Kerecis Limited$9K
  • Arthrex$5K
  • Integra Lifesciences Corporation$5K
  • AbbVie$5K
  • KCI USA, Inc.$3K
  • Musculoskeletal Transplant Foundation Inc.$1K
  • plus $8K from 33 others

What the payments were for

  • Consulting fees$5,40015%
  • Speaking & faculty fees$8,25023%
  • Travel & lodging$2,8658%
  • Food & beverage$15,82844%
  • Education$3,80911%
  • Entertainment$970%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$36,249 in reported general payments places this provider in the 85th percentile of 60 surgery of the hand providers in Florida.

See all surgery of the hand providers in Florida

Medicare billing

Part B allowed, 2024
$56,664
Medicare patients
55
Services billed
498

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim12$77

Paid to pharmacies, not to this prescriber.

Other surgery of the hand in Coral Gables

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →